CYP19A1 and diffuse large B-cell lymphoma: From a total cohort of 153,883 BC patients, 106 patients (0.07%) were diagnosed with DLBCL within 5 years after the start of BC treatment, of whom 24 were treated with tamoxifen, 31 were treated with an aromatase inhibitor, and 51 did not receive any HT.